OK205 is a traditional Korean prescription containing water-soluble chitosan, glucosamine HCl, chondroitin sulfate, and extract of herbal medicine, and has been used commercially to treat rheumatoid arthritis (RA). Because infiltrated mast cells and their mediators may contribute to the initiation and progression of the inflammatory process and matrix degradation of RA, we tested the inhibitory effects of OK205 on cytokine production in a human mast cell line (HMC-1 cells) . Production of tumor necrosis factor-a a was significantly decreased to 0.091؎0.010 ng/ml after treatment of HMC-1 cells with OK205 100 m mg/ml. The inhibition rate was about 43.57%. In addition, production of interleukin-6 in OK205 1 pg/ml-treated cells was 2.779؎0.071 ng/ml, and the inhibition rate was about 50.22%. However, OK205 did not significantly inhibit the production of interleukin-8. These findings may help in understanding the mechanism of action of OK205, leading to control of mast cells in inflammatory conditions like RA.
OK205 is composed of several materials and the components are interesting from the viewpoint of relieving rheumatoid arthritis (RA). However, it is still unclear how it regulates the immune or inflammatory responses.
RA is a typical rheumatic disease characterized by chronic inflammatory disease that leads to cartilage destruction, joint deformity, and disability. 1, 2) In the rheumatoid lesion, profound hypertrophic changes of the synovium with infiltration of immune cells, increased vascularity, and hyperplasia result in the formation of a synovial pannus that invades cartilage and bone.
3) The cellular composition at sites of cartilage erosion varies greatly, such as macrophages, fibroblasts, mast cells, polymorphonuclear lymphocytes, and dendrocytes. 4) Although mast cells have been viewed primarily in the central role of immediate-type hypersensitivity reactions, 5, 6 ) the significant contribution of the mast cells in the pathogenesis of rheumatic diseases has recently become more evident. Accumulation of mast cells and their activation/degranulation have been demonstrated in rheumatoid synovial tissues as well as in the synovial fluids. [7] [8] [9] Activated mast cells synthesize prostaglandins and leukotrienes and produce both preformed and newly synthesized cytokines such as tumor necrosis factor (TNF)-a and interleukins. 10) Thus infiltrated mast cells and their mediators may contribute to the initiation and progression of the distributive inflammatory process and matrix degradation of RA. 11, 12) Inhibition of mast cell accumulation or activation is becoming a new therapeutic approach to controlling chronic inflammation in the rheumatoid lesion.
The involvement of proinflammatory cytokines, particularly TNF-a resulting in local inflammation, in the pathogenesis of RA, is now well accepted. [13] [14] [15] TNF-a, perhaps the best studied, is an autocrine stimulator as well as a potent inducer of other inflammatory cytokines, including interleukin (IL)-1, IL-6, IL-8, and granulocyte-monocyte colonystimulating factor. 16, 17) IL-1 is also considered to be the primary mediator of the inflammation associated with the pathogenesis of RA. 18) Overproduction of IL-1 and TNF-a initiates the pathophysiologic processes that lead to symptoms of RA.
19) IL-6 is produced by various types of cell including synoviocytes and mast cells and plays a critical role in the pathology of RA. [20] [21] [22] IL-8, the first human chemokine to be characterized, is often upregulated at inflammatory sites including rheumatoid lesions. 23, 24) Accordingly, blockade of these cytokines is now the main target and new approach in the treatment of RA. 25, 26) We used cyclosporin A (CsA), an immunosuppressant, as a positive control. In the previous report, CsA inhibited cytokine gene expression such as that of TNF-a, IL-5, IL-6, and IL-8. 27, 28) Moreover, treatment with CsA plus another RA agent like methotrexate was effective in treating RA. 29) In the present study, we showed that OK205 inhibited the production of phorbol-12-myristate-13-acetate (PMA) plus A23187-induced cytokines from a human mast cell line (HMC-1 cells).
MATERIALS AND METHODS

Reagents and Antibodies
Cell culture medium, Iscove's modified Dulbecco's medium (IMDM), was purchased from Gibco BRL (Grand Island, NY, U.S.A.). 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide (MTT), PMA, A23187, 2,2-azio-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS), CsA, and other reagents were obtained from Sigma (St. Louis, MO, U.S.A.). Anti-human TNF-a and IL-1b Ab, biotinylated anti-human TNF-a and IL-1b Ab, and recombinant human TNF-a and IL-1b were purchased from R&D Systems (Minneapolis, MN, U.S.A.). Anti-human IL-6, and IL-8 Ab, biotinylated anti-human IL-6 and IL-8 Ab and recombinant human IL-6 and IL-8 were obtained from PharMingen (Cambridge, U.K.).
Preparation of OK205 OK205 was composed of water- Cell Culture and Stimulation HMC-1 cells were grown in IMDM supplemented with penicillin 100 units/ml, streptomycin 100 mg/ml, monothioglycerol 10 Ϫ5 M, and 10% heatinactivated FBS at 37°C in 5% CO 2 and 95% humidity. HMC-1 cells (1ϫ10 6 cells/ml) were treated with OK205 or CsA (5 mg/ml) for 30 min prior to stimulation with PMA 50 nM plus 1 mM A23187 and incubated at 37°C for an additional time.
MTT Assay To test the viability of cells, the MTT colorimetric assay was performed as described previously. 30) Briefly, HMC-1 cells (1ϫ10 6 cells/ml) were incubated for 8 h after stimulation in the presence or absence of OK205 (10 ng/ml, 10 mg/ml). After the addition of MTT solution, the cells were incubated at 37°C for 4 h. The crystallized MTT was dissolved and the absorbance measured at 540 nm.
Assay of Cytokine Production Secreted cytokine levels in culture supernatants of HMC-1 were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) according to manufacturer's protocol (for TNF-a and IL-1b assay, R&D Systems; for IL-6 and IL-8 assay, PharMingen). Absorption of the avidin-horseradish peroxidase color reaction was measured at 405 nm and compared with serial dilutions of human recombinants as a standard.
Statistical Analysis Each value represents the meanϮ S.E.M. of different experiments under the same conditions. Student's t-test was used to make a statistical comparison between the groups. Results of pϽ0.05 were considered statistically significant.
RESULTS
Effects of OK205 on HMC-1 Viability
To test the cytotoxic effects of OK205, we performed the MTT assay in HMC-1 cells. OK205 (10 ng/ml, 10 mg/ml) did not significantly affect cell viability in each condition and had no toxicity on HMC-1 cells (data not shown).
Effects of OK205 on Cytokine Production HMC-1 cells can induce the activation of nonphysiologic agents such as PMA or A23187 and release various cytokines. The concentration of TNF-a was 0.021Ϯ0.006 ng/ml in nonstimulated cells and 0.145Ϯ0.007 ng/ml in PMA plus A23187-stimulated cells (pϽ0.001). However, the production was significantly decreased to 0.091Ϯ0.010 ng/ml after treatment with OK205 100 mg/ml (pϽ0.001). CsA (5 mg/ml) also inhibited TNF-a production by 0.053Ϯ0.005 ng/ml (Fig. 1) . However, 10 ng/ml, 0.1 ng/ml, and 1 pg/ml of OK205 did not inhibit TNF-a production by activated HMC-1 cells (data not shown).
The concentration of IL-6 was 0.308Ϯ0.087 ng/ml in nonstimulated cells and 5.272Ϯ0.190 ng/ml in PMA plus A23187-stimulated cells. We also measured the IL-6 concentration in supernatants incubated with OK205 or CsA. The concentration of IL-6 in OK205 1 pg/ml-stimulated cells was 2.779Ϯ0.071 ng/ml, and the inhibition rate was about 50.22%. CsA (5 mg/ml) decreased IL-6 production (4.082Ϯ 0.124 ng/ml), and the inhibition rate was about 23.97% (Fig. 2) .
IL-8 production was 0.089Ϯ0.013 ng/ml in nonstimulated cells and 2.599Ϯ0.116 ng/ml in PMA plus A23187-stimu- Cells (1ϫ10 6 cells/ml) were incubated in the presence or absence of OK205 (10 ng/ml, 1 mg/ml, 100 mg/ml) for 30 min prior to stimulation with PMA plus A23187, and TNF-a in supernatant was measured after 8-h incubation. CsA (5 mg/ml) was used as a positive control compared with OK205. Asterisks correspond to the levels of significance assessed using Student's t-test. * pϽ0.001 compared with nonstimulated cells, and * * pϽ0.001 compared with the PMA plus A23187-stimulated value. All data represent the meanϮS.E.M. of four independent experiments. 1, Nonstimulated cells; 2, PMA plus A23187; 3, OK205 (10 ng/ml)ϩPMA plus A23187; 4, OK205 (1 mg/ml)ϩPMA plus A23187; 5, OK205 (100 mg/ml)ϩPMA plus A23187; 6, CsA (5 mg/ml)ϩPMA plus A23187. Fig. 2 . Effect of OK205 on PMA Plus A23187-Induced IL-6 Production from HMC-1 Cells Cells (1ϫ10 6 cells/ml) were incubated in the presence or absence of OK205 (1 pg/ml-100 mg/ml) for 30 min prior to stimulation with PMA plus A23187, and IL-6 in the supernatant was measured after 8-h incubation. CsA (5 mg/ml) was used as a positive control compared with OK205. Asterisks correspond to the levels of significance assessed using the Student's t-test. * pϽ0.001 compared with nonstimulated cells, and * * pϽ0.001, # pϽ0.01 compared with the PMA plus A23187-stimulated value. All data represent the meanϮS.E.M. of four independent experiments. 1, Nonstimulated cells; 2, PMA plus A23187; 3, OK205 (1 pg/ml)ϩPMA plus A23187; 4, OK205 (10 pg/ml)ϩPMA plus A23187; 5, OK205 (100 pg/ml)ϩPMA plus A23187; 6, OK205 (1 ng/ml)ϩPMA plus A23187; 7, OK205 (10 ng/ml)ϩPMA plus A23187; 8, OK205 (100 ng/ml)ϩPMA plus A23187; 9, OK205 (1 mg/ml)ϩPMA plus A23187; 10, OK205 (10 mg/ml)ϩPMA plus A23187; 11, OK205 (100 mg/ml)ϩPMA plus A23187; 12, CsA (5 mg/ml)ϩPMA plus A23187. lated cells (pϽ0.001). CsA decreased IL-8 production (0.934Ϯ0.069 ng/ml; pϽ0.001), but OK205 treatment did not show a significant difference (Fig. 3) .
OK205 10 ng/ml inhibited IL-1b production by 41.37%, but OK205 (100 mg/ml and 1 pg/ml) did not inhibit IL-1b production by activated HMC-1 cells (data not shown).
DISCUSSION
In the present study, we observed that OK205 significantly inhibited PMA plus A23187-induced TNF-a, IL-6, and IL-1b production. However, we did not observe an inhibitory effect of OK205 on IL-8 production.
TNF-a, IL-6, and IL-1b are known to be key cytokines that contribute to inflammation in RA, and therapies targeting these cytokines have had considerable clinical success. 31, 32) Higher levels of IL-6 have been found in the sera of RA patients compared with controls, and in synovial fluid compared with serum, reflecting local production by the rheumatoid synovium. 33, 34) OK205 inhibited TNF-a, IL-6, and IL-1b production by activated mast cells. Surprisingly, the dose of OK205 that inhibits the production of TNF-a, IL-6, and IL-1b is different. Since OK205 is composed of several constituents such as chitosan, glucosamine HCl, chondroitin, and several herbs, it is possible that the different effects of OK205 on different types of cytokine production might be caused by different substances among the constituents of OK205. Further study is needed to verify the reasons for the differences.
Chitosan, the N-deacetylated derivative of chitin, has been recommended as a suitable functional material because of its biocompatibility, biodegradability, nontoxicity, and adsorption properties.
35) It was reported that chitosan can regulate cell biology such as differentiation, proliferation, and cytokine production. 36, 37) Glucosamine has a potentially chondroprotective property. Glucosamine and chondroitin have been shown to be effective in animal models of osteoarthritis and in the treatment of patients with osteoarthritis. 38, 39) In the previous study, we found that the Oriental medications Daeganghwal-tang and Cool-cool for RA inhibited PMA plus A23187-induced inflammatory cytokine production such as that of TNF-a, IL-1b, IL-6, and IL-8. 21, 40) OK205 also inhibited the inflammatory cytokines such as TNF-a, IL-1b, and IL-6, but not IL-8. The human chemokine IL-8 released from mast cells might act on surrounding cells such as neutrophils, T cells, B cells, and eosinophils and induce migration and activation of inflammatory effector cells. [41] [42] [43] [44] The OK205 doses used may not affect the migration of these cells or the release response may be different from that of Daeganghwal-tang and Cool-cool. The main effect of OK205 in RA may be associated with inflammatory cytokine blockage.
This study investigated the effects of OK205 in an in vitro experimental model. The effective concentration is too high, which means that a clinical application is likely not possible. The results of this study may provide clues to the pharmacologic function of the formula for future in vivo study. In addition, because TNF-a, IL-6, and IL-1b are dominantly produced in other types of cells, such as macrophages, synoviocytes, T cells, and so on, we need to confirm the present results in these cells. Cells (1ϫ10 6 cells/ml) were incubated in the presence or absence of OK205 (1 pg/ml-100 mg/ml) for 30 min prior to stimulation with PMA plus A23187, and IL-8 in the supernatant was measured after 8-h incubation. CsA (5 mg/ml) was used as a positive control compared with OK205. Asterisks correspond to the levels of significance assessed using the Student's t-test. * pϽ0.001 compared with nonstimulated cells, and * * pϽ0.001 compared with the PMA plus A23187-stimulated value. All data represent the meanϮS.E.M. of four independent experiments. 1, Nonstimulated cells; 2, PMA plus A23187; 3, OK205 (1 pg/ml)ϩPMA plus A23187; 4, OK205 (10 pg/ml)ϩPMA plus A23187; 5, OK205 (100 pg/ml)ϩPMA plus A23187; 6, OK205 (10 ng/ml)ϩPMA plus A23187; 7, OK205 (1 mg/ml)ϩPMA plus A23187; 8, OK205 (10 mg/ml)ϩPMA plus A23187; 9, OK205 (100 mg/ml)ϩPMA plus A23187; 10, CsA (5 mg/ml)ϩPMA plus A23187.
